Revenue Breakdown
Composition ()
No data
Revenue Streams
Immutep Ltd (IMMP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cancer Immunotherapy, accounting for 51.4% of total sales, equivalent to AUD 2.11M. Another important revenue stream is Unallocated. Understanding this composition is critical for investors evaluating how IMMP navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Immutep Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1170.97%, while the net margin is -1095.35%. These profitability ratios, combined with a Return on Equity (ROE) of -61.85%, provide a clear picture of how effectively IMMP converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IMMP competes directly with industry leaders such as EPRX and CRMD. With a market capitalization of $393.48M, it holds a significant position in the sector. When comparing efficiency, IMMP's gross margin of 100.00% stands against EPRX's N/A and CRMD's 89.26%. Such benchmarking helps identify whether Immutep Ltd is trading at a premium or discount relative to its financial performance.
